Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Fabio PS Santos
Efficacy of Ruxolitinib for Myelofibrosis
Expert Opinion on Pharmacotherapy
Medicine
Pharmacology
Related publications
Safety and Efficacy of Ruxolitinib in Myelofibrosis Patients Without Splenomegaly
British Journal of Haematology
Hematology
Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Ruxolitinib as an Emerging Treatment in Myelofibrosis
Blood and Lymphatic Cancer: Targets and Therapy
JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis
New England Journal of Medicine
Medicine
Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis
Blood Cancer Journal
Oncology
Hematology
Critical Appraisal of the Role of Ruxolitinib in Myeloproliferative Neoplasm-Associated Myelofibrosis
OncoTargets and Therapy
Oncology
Pharmacology
Primary Myelofibrosis Associated Glomerulopathy: Significant Improvement After Therapy With Ruxolitinib
BMC Nephrology
Nephrology
U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients With Intermediate and High-Risk Myelofibrosis
Clinical Cancer Research
Cancer Research
Oncology
Cost-Effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
Journal of Health Economics and Outcomes Research